1Hale G, Rocbester R, Heslop H, et al. Hemorrhagic cystitis after allogeneic bone marrow transplantation in children:clinical characteristics and outcome. Biol Blood Marrow Transplant,2003,9(11):698-705.
2Carreras E,Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation:a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood, 1998,92(10):3599-3604.
3Weiner RS,Bortin MM,Gale RP,et al. Interstitial pneumonitis after bone marrow transplantation:assessment of risk factors. Ann InternMed, 1986,104(2): 168-175.
4Fraser GA, Walker II. Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. Biol Blood Marrow Transplant,2004,10(5):257-297.
2Gaziev D, Lucarelli G. Novel approaches to the treatment of chronic graft-versus-host disease. Expert Opin Investig Drugs ,2001,10:909-923.
3Nagler A, Menachem Y, Ilan Y. Amelioration of steroid-resistant chronic graft-versus-host-mediated liver disease via tacrolimus treatment. J Hematother Stem Cell Res ,2001,10:411-417.
4Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood, 2001,97:1219-1226.
5Mohty M, Kuentz M, Michallet M,et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood,2002,100:3128-3134.
6Zecca M, Prete A, Rondelli R, et al. Chronic graft-versus-host disease in children:incidence,risk factors, and impact on outcome.Blood, 2002,100:1192-1200.
7Gaziev,Lucarelli G,Polchi P,et al.Three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease.Bone Marrow Transplant,2001,27(1):45-51.
8Mookerjee B,Altomone V,Vogelsang G.Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus.Bone Marrow Transplantation,1999,24:517.
9Storek J,Sawson MA,Storer B,et al.Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.Blood,2001,97:3380-3389.
3Remberger M, Mattsson J, Hassan Z, et al. Risk factors for acute graft- versus - host disease graes Ⅱ- Ⅳ after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors - a single centre study[ J]. Bone Marrow Transplant ,2007 [ Epub ahead of print].
4WojnarJ, Giebel S, Krawczyk - Kulis M,et all Acute graft versus - host disease. The incidence and risk factors [ J ]. Ann Transplant, 2006, 11(1):16-23.
5Meisel R,Laws HJ,Balzer S,et al. Comparable long -term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies [J]. Blood Marrow Transplant,2007,13( 11 ) :1338 - 1345.
6Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem -cell compared with bone marrow transplantation in the management of hematologic malignancies:An individual patient data meta- analysis of nine randomized trials [ J ]. J Clin Oncol,2005,23 ( 22 ) : 5074 - 5080.
7Miura Y,Thoburn C J, Bright EC,et al. Association of Foxp3 regulatory gene expression with graft - versus - host disease [ J ]. Blood, 2004,104 (7) :2187 - 2193.
9Gaziev D, Galimberti M, Lucarelli G, et al. Bone marrow transplantation from alternative donors for thalassemia: HLA - phenotypically identical relative and HLA - nonidentical sibling or parent transplants [ J ]. Bone Marrow Transplant ,2000,25 ( 8 ) :815 - 821.
10Remberger M, Beelen DW, Fauser A, et al. Increased risk of extensive chronic graft - versus - host disease after all ogeneic peripheral blood stem cell transplantation using unrelated donors [ J]. Blood, 2005,105 (2) :548 -551.
